Incheon, South Korea and Zug, Switzerland -- Samsung Biologics, through its Swiss subsidiary Samsung Peptide AG, published the formal tender offer prospectus for PolyPeptide Group AG, setting a cash price of CHF 44.31 per share and an implied equity value of approximately CHF 1.46 billion. The filing, made in Zug, Switzerland, follows a pre-announcement issued July 20, 2026, and covers all publicly held shares of the peptide-focused contract manufacturer listed on the SIX Swiss Exchange. The main acceptance period runs from Sept. 15 to Oct. 12, 2026.